Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-19T12:33:05.529Z Has data issue: false hasContentIssue false
  • English
  • Français

Changes in cigarette consumption in psychiatric patients: impact on side-effects or the efficacy of clozapine and olanzapine

Published online by Cambridge University Press:  24 June 2014

Subodh Jain ,
Jatinder M. Chawla ,
Thimmaiah G. Theethira ,
Martin Strassnig  and
K. N. Roy Chengappa
Subodh Jain
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Jatinder M. Chawla
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Ram Manohar Lohia Hospital, New Delhi, India Mayview State Hospital, Bridgeville, PA, USA
Thimmaiah G. Theethira
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Martin Strassnig
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
K. N. Roy Chengappa*
Affiliation:
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Mayview State Hospital, Bridgeville, PA, USA
*
K. N. Roy Chengappa, MD, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA Tel: 412 246 5006; Fax: 412 246 5007; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Comment & Critique
Information
Acta Neuropsychiatrica , Volume 20 , Issue 6 , December 2008 , pp. 324 - 326
Copyright
Copyright © 2008 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lasser, K, Boyd, JW, Woolhandler, S, Himmelstein, DU, McCormick, D, Bor, DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606–2610. CrossRefGoogle ScholarPubMed
Gonzalez-Pinto, A, Gutierrez, M, Ezcurra, Jet al. Tobacco smoking and bipolar disorder. J Clin Psychiatry 1998;59:225–228. CrossRefGoogle ScholarPubMed
Uçok, A, Polat, A, Bozkurt, O, Meteris, H. Cigarette smoking among patient with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004;58:434–437. CrossRefGoogle ScholarPubMed
Dudass, MM, George, TP. Non-nicotine pharmacotherapies for nicotine dependence. Essent Psychopharmacol 2005;6:158–172. Google Scholar
Strassnig, M, Brar, JS, Ganguli, R. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res 2006;86:269–275. CrossRefGoogle ScholarPubMed
Shrenk, D, Brockmeier, D, Morike, Ket al. A distribution study of CYP1A2 phenotypes among smokers & non smokers in a cohort study of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998;53:361–367. CrossRefGoogle Scholar
Meyer, JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001;21:569–574. CrossRefGoogle Scholar
Skogh, E, Reis, M, Dahl, ML, Lundmark, J, Bengtsson, F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in naturalistic clinical setting. Ther Drug Monit 2002;24:518–526. CrossRefGoogle ScholarPubMed
Zullino, DF, Delessert, D, Eap, CB, Preisig, M, Baumann, P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141–143. CrossRefGoogle ScholarPubMed
Bertilsson, L, Carrillo, JA, Dahl, MLet al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:15–22. CrossRefGoogle ScholarPubMed
Ozdemir, V, Kalow, W, Posner, Pet al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001;21:398–407. CrossRefGoogle ScholarPubMed
Eiermann, B, Engel, G, Johansson, Iet al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439–446. CrossRefGoogle Scholar
Seppala, NH, Leinonen, EVJ, Lehtonen, MLet al. Clozapine serum concentrations are lower in smoking than in non smoking schizophrenia patients. Pharmacol Toxicol 1999;85:244–246. CrossRefGoogle Scholar
Zevin, S, Benowitz, NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36:425–438. CrossRefGoogle ScholarPubMed
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, Lennard, MS, Tucker, GT, Flanagan, RJ. Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations.: a predictive model and nomograms to aid clozapine dose adjustments and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24:70–78. CrossRefGoogle Scholar
Faber, MS, Fuhr, U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178–184. CrossRefGoogle ScholarPubMed
Byerly, MJ, DeVane, CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177–187. CrossRefGoogle ScholarPubMed
Skogh, E, Bengtsson, F, Nordin, C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999;21:580–582. CrossRefGoogle ScholarPubMed
George, TP, Vessicchio, JC, Termine, Aet al. A placebo-controlled study of buproprion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53–61. CrossRefGoogle Scholar
Evins, AE, Cather, C, Deckersbach, Tet al. A double-blind placebo-controlled trial of buproprion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218–225. CrossRefGoogle Scholar
Relling, MV, Lin, JS, Ayers, GD, Evans, WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643–658. CrossRefGoogle ScholarPubMed
Berk, M, Should we be targeting smoking cessation as a routine intervention? Acta Neuropsychiatr 2007;19:131–132. CrossRefGoogle Scholar